BioSpace News Archive

BioCare, Inc., a leading specialty distributor of life-saving therapies, announced the launch of LogiCare3PL, a third-party logistics offering that will provide specialty pharmaceutical manufacturers all-inclusive order to cash, inventory management, packaging and shipping services.

According to Emergen Research, the global neurostimulation devices market size was USD 6.30 billion in 2020 and is expected to reach USD 15.42 billion in 2028 and register a revenue CAGR of 12.6% during the forecast period, 2021-2028.

According to Emergen Research, the global prenatal testing and newborn screening market size was USD 4,652.21 million in 2020 and is expected to reach USD 12.23 billion in 2028 and register a revenue CAGR of 12.8% during the forecast period, 2021-2028.

HeartPoint Global, a leading medical device company dedicated to providing high-quality, minimally invasive cardiac care globally, today announced a major milestone in ongoing pre-clinical trials of the HeartPoint Global Implant System (HPGS) in Israel.

Access Vascular, Inc. announced it has been named a winner in the 2022 BIG Innovation Awards presented by the Business Intelligence Group.

PROCEPT® BioRobotics Corporation, a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, reported preliminary unaudited revenue for the fourth quarter and fiscal year ended December 31, 2021.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy, announced its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2021.

Iridex Corporation provided preliminary unaudited operational and financial results for the fourth quarter and full year ended January 1, 2022.

Aclaris Therapeutics, Inc. provides an update on the status of certain of its clinical programs and on its research and development operations.

Glaukos Corporation (NYSE: GKOS), today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.